Phio Pharmaceuticals Corp
$ 1.29
15.18%
11 Feb - close price
- Market Cap 15,787,100 USD
- Current Price $ 1.29
- High / Low $ 1.44 / 1.19
- Stock P/E N/A
- Book Value 2.10
- EPS -2.09
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.56 %
- ROE -1.02 %
- 52 Week High 3.48
- 52 Week Low 0.81
About
Phio Pharmaceuticals Corp. The company is headquartered in Marlborough, Massachusetts.
Analyst Target Price
$14.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-07 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-04-01 | 2024-03-20 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-22 |
| Reported EPS | -0.44 | -0.45 | -0.9379 | -0.85 | -1.54 | -3.62 | -0.85 | -0.85 | -1.14 | -1.4747 | -3.1535 | -2.4 |
| Estimated EPS | -0.4 | -0.36 | None | -1.23 | -4.14 | -4.59 | -1.3 | -1.3 | -1.43 | None | None | -3.24 |
| Surprise | -0.04 | -0.09 | 0 | 0.38 | 2.6 | 0.97 | 0.45 | 0.45 | 0.29 | 0 | 0 | 0.84 |
| Surprise Percentage | -10% | -25% | None% | 30.8943% | 62.8019% | 21.1329% | 34.6154% | 34.6154% | 20.2797% | None% | None% | 25.9259% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHIO
2026-02-11 14:58:20
Phio Pharmaceuticals Corp. (PHIO) stocks have risen by 21.43% following positive FDA designations and promising results. The upcoming DealFlow Discovery Conference, where CEO Alex Reyes is rumored to present, is expected to generate significant investor interest and potential stock movement, possibly through new partnerships or funding. Despite a recent net income loss, PHIO shows financial resilience with robust cash reserves and a strong current ratio, indicating potential for strategic acquisitions and a significant market rebound.
2026-02-11 09:58:20
Phio Pharmaceuticals' stock surged in premarket trading following positive safety and response data from its Phase 1b PH-762 skin cancer trial. The company reported no dose-limiting toxicities or serious adverse events and significant pathological responses, especially at the highest dose. Phio Pharmaceuticals plans to submit a proposal to the FDA in Q2 2026 for the next steps in developing PH-762, an siRNA-based therapy targeting the PD-1 pathway.
2026-02-10 19:28:46
HC Wainwright & Co. analyst Matthew Keller has reiterated a Buy rating for Phio Pharma (PHIO) with a consistent price target of $14.00, reflecting ongoing confidence in the company's market position. This rating is consistent with previous assessments from the firm. Phio Pharma, a clinical-stage biotechnology company, is developing therapeutics using its INTASYL platform to enhance immune cell efficacy against tumor cells.
2026-02-10 16:15:18
Phio Pharmaceuticals (NASDAQ: PHIO) shares surged after the company announced positive Phase 1b clinical trial results for its lead candidate, PH-762. The trial for skin cancer patients showed an 85% pathological response rate and complete tumor clearance in a significant number of patients at the highest dose. The company plans an FDA submission in Q2 2026 to discuss future clinical study design.
2026-02-10 14:58:18
Phio Pharmaceuticals Corp (NASDAQ:PHIO) stock surged following positive results from its Phase 1b clinical trial for the cancer treatment PH-762. The INTASYL compound achieved an 85% pathological response rate in the final cohort, with 6 out of 7 patients responding to treatment, including 4 complete responses. The company plans to seek FDA guidance for the next clinical study steps and is advancing manufacturing for future pivotal human trials.
2026-02-10 12:58:18
Phio Pharmaceuticals announced positive safety results from its Phase 1b trial of PH-762 in skin cancers, with no serious adverse events reported among 22 patients. The trial showed a high pathological response rate of 85% at the highest dose cohort and a 65% overall response rate in cutaneous squamous cell carcinoma. The company is also progressing with manufacturing for future studies and potential pivotal trials.
